Popular Articles

Lack Of Happiness Hormone Serotonin In The Brain Causes Impaired Maternal Behavior In Mice
A lack of serotonin, commonly known as the "happiness hormone", in the brain slows the growth of mice after birth and is responsible for impaired maternal behavior later in life. This was the result of research conducted by Dr. Natalia Alenina, Dana Kikic, and Professor Michael Bader of the Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch, Germany. At the same time, the researchers discovered that the presence of serotonin in the brain is not crucial for the survival of the animals. Furthermore, they were able to confirm that there are two strictly separate pathways of serotonin production: One gene is responsible for the formation of serotonin in the brain, another gene for the production of the hormone in the body (PNAS, June 23, 2009, Vol. 106, No. 25, pp 10332-10337)*.
buy viagra
Improve Communication With Your Healthcare Practitioner With The AGS Foundation For Health In Aging's New Health Tip Sheet
Good communication between patients and their healthcare practitioners is essential to good care. To help older adults better communicate with their healthcare providers, the American Geriatrics Society"s Foundation for Health in Aging (FHA) has released a new, easily understandable tip sheet for older people and their caregivers.
News of the day
Another Mystery In B Lymphocyte Development Solved By NYU School Of Medicine Pathology Researchers
A new study published online in Nature Immunology ahead of the June 2009 print issue has found that homologous immunoglobulin (lg) alleles pair up in the nucleus at stages that coincide with V(D)J recombination of the heavy and light chain (Igh and Igk) loci. Researchers led by Jane A. Skok Ph.D., assistant professor in the Department of Pathology at NYU School of Medicine and a member of the NYU Cancer Institute, showed that the V(D)J recombinase, which consists of the RAG1 and RAG2 proteins, mediates this pairing and helps ensure that only one allele undergoes recombination at a time (a process known as allelic exclusion).
Oncology

Abbott And AstraZeneca Extend Relationship To Include Co-promotion Of TRILIPIX(R) (fenofibric Acid)

Abbott and AstraZeneca announced today that they have entered into an agreement for AstraZeneca to co-promote Abbott"s TRILIPIX® (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed. "Abbott"s portfolio of lipid therapies is designed to help physicians manage a patient"s total lipid profile," said Jeffrey Stewart, divisional vice president, Primary Care, Abbott. "With AstraZeneca"s established presence in the cardiovascular space, this agreement allows Abbott to expand visibility and education of TRILIPIX among physicians whose patients may benefit from this medication." "Part of AstraZeneca"s corporate strategy is to establish successful external collaborations. AstraZeneca has a long-standing commitment to cardiovascular health and has an established presence in the cholesterol market. This agreement allows us to further strengthen our presence with physicians by including TRILIPIX as an offering to physicians for patients with dyslipidemia," said Jim Helm, vice president, cardiovascular, AstraZeneca US. "With clinical data to support its use in helping certain patients with mixed dyslipidemia to manage all three key lipids, TRILIPIX is another important therapeutic option we can now offer physicians." TRILIPIX is a prescription medicine that is used along with diet to lower triglycerides and LDL (bad) cholesterol, and increase HDL (good) cholesterol. TRILIPIX is also used along with diet to lower triglycerides and increase HDL cholesterol in people who are at high risk of heart disease and are taking a statin medicine to control their LDL cholesterol. TRILIPIX has not been shown to prevent heart attacks or stroke more than a statin alone. TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease or by nursing mothers. People should tell their healthcare providers about all the medicines they take. Blood tests are needed before and during treatment with TRILIPIX to check for liver problems. A healthcare provider should be contacted if serious side effects such as unexplained muscle pain, tenderness, or weakness develop. The risk of these side effects may be higher when TRILIPIX is used with a statin. Other serious side effects may include abdominal pain, nausea, or vomiting. About the Agreement This agreement is the second co-promotion agreement between AstraZeneca and Abbott. In August of 2008, the companies announced a non-exclusive agreement for Abbott to co-promote AstraZeneca"s CRESTOR® alongside AstraZeneca in the United States. Important Safety Information About TRILIPIX® (fenofibric acid) TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease, nursing mothers, or those allergic to any product ingredient. Unexplained muscle pain, tenderness, or weakness, particularly when occurring with tiredness and fever, may be a sign of a serious side effect and should be reported to a healthcare provider right away. Rarely, muscle-related problems can cause kidney damage and can be fatal. The risk of these side effects may be increased when TRILIPIX is used with a statin. Patients should tell their healthcare provider about all the medicines they take. Blood tests should be performed before and during treatment with TRILIPIX to check for liver or kidney problems. Patients should contact their healthcare provider if they experience abdominal pain, nausea, or vomiting while taking TRILIPIX. These may be signs of inflammation of the gallbladder or pancreas. Women who are pregnant should not take statins and should talk with their healthcare provider about TRILIPIX if they are pregnant or may become pregnant. The most common side effects with TRILIPIX include headache, heartburn, nausea, muscle aches, and increases in muscle or liver enzymes that are measured by blood tests. Full Prescribing Information is available at http://www.rxabbott.com/pdf/trilipix_pi.pdf. Visit http://www.trilipix.com or call Abbott Medical Information at 1-800-633-9110 for more information about TRILIPIX. About AstraZeneca AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world"s leading pharmaceutical companies with global healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business. For more information visit http://www.astrazeneca.com. Abbott Laboratories


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):